Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after

• Tác giả: Emmanuel S Antonarakis, Ali T Arafa, Delphine L Chen, Heather H Cheng, Laura S Graham, Roman Gulati, Michael C Haffner, Jessica E Hawley, Thomas A Hope, Amir Iravani, Deepak Kilari, Soon Khai Low, George Mo, Robert B Montgomery, Peter S Nelson, Colin C Pritchard, Ruben Raychaudhuri, Michael T Schweizer, Abuzar Moradi Tuchayi, Evan Y Yu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 621.374 Instruments for measuring specific electrical quantities
• Thông tin xuất bản: Netherlands : European urology oncology , 2025
• Bộ sưu tập: NCBI
• ID: 193579

Tóm tắt

BACKGROUND AND OBJECTIVE: The prostate-specific membrane antigen (PSMA) radioligand METHODS: This retrospective study included 100 patients with a PARPi-qualifying HRR alteration treated with LuPSMA. Clinical outcomes on LuPSMA, including PSA KEY FINDINGS AND LIMITATIONS: PSA CONCLUSIONS AND CLINICAL IMPLICATIONS: PARPi exposure is associated with inferior LuPSMA outcomes, particularly for patients with BRCA2 alterations. These findings suggest potential cross-resistance and underscore the need for prospective studies assessing the optimal sequencing of these agents.